SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366.
  • 2
    Motzer RJ,Hutson TE,Tomczak P,Michaelson MD,Bukowski RM,Rixe O,Oudard S,Negrier S,Szczylik C,Kim ST,Chen I,Bycott PW, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 11524.
  • 3
    Escudier B,Eisen T,Stadler WM,Szczylik C,Oudard S,Siebels M,Negrier S,Chevreau C,Solska E,Desai AA,Rolland F,Demkow T, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 12534.
  • 4
    Latif F,Tory K,Gnarra J,Yao M,Duh FM,Orcutt ML,Stackhouse T,Kuzmin I,Modi W,Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 131720.
  • 5
    Seizinger BR,Rouleau GA,Ozelius LJ,Lane AH,Farmer GE,Lamiell JM,Haines J,Yuen JW,Collins D,Majoor-Krakauer D. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988; 332: 2689.
  • 6
    Linehan WM,Walther MM,Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170: 216372.
  • 7
    Gnarra JR,Tory K,Weng Y,Schmidt L,Wei MH,Li H,Latif F,Liu S,Chen F,Duh FM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 8590.
  • 8
    Shuin T,Kondo K,Torigoe S,Kishida T,Kubota Y,Hosaka M,Nagashima Y,Kitamura H,Latif F,Zbar B. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994; 54: 28525.
  • 9
    Iliopoulos O,Ohh M,Kaelin WG,Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998; 95: 116616.
  • 10
    Blankenship C,Naglich JG,Whaley JM,Seizinger B,Kley N. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 1999; 18: 152935.
  • 11
    Cockman ME,Masson N,Mole DR,Jaakkola P,Chang GW,Clifford SC,Maher ER,Pugh CW,Ratcliffe PJ,Maxwell PH. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275: 2573341.
  • 12
    Kim WY,Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 49915004.
  • 13
    Brauch H,Weirich G,Brieger J,Glavac D,Rödl H,Eichinger M,Feurer M,Weidt E,Puranakanitstha C,Neuhaus C,Pomer S,Brenner W, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000; 60: 19428.
  • 14
    Kondo K,Yao M,Yoshida M,Kishida T,Shuin T,Miura T,Moriyama M,Kobayashi K,Sakai N,Kaneko S,Kawakami S,Baba M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34: 5868.
  • 15
    Kim JH,Jung CW,Cho YH,Lee J,Lee SH,Kim HY,Park J,Park JO,Kim K,Kim WS,Park YS,Im YH, et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005; 13: 85964.
  • 16
    Yao M,Yoshida M,Kishida T,Nakaigawa N,Baba M,Kobayashi K,Miura T,Moriyama M,Nagashima Y,Nakatani Y,Kubota Y,Kondo K. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94: 156975.
  • 17
    Wykoff CC,Beasley NJ,Watson PH,Turner KJ,Pastorek J,Sibtain A,Wilson GD,Turley H,Talks KL,Maxwell PH,Pugh CW,Ratcliffe PJ, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 707583.
  • 18
    Dorai T,Sawczuk I,Pastorek J,Wiernik PH,Dutcher JP. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest 2006; 24: 75479.
  • 19
    Swinson DE,Jones JL,Richardson D,Wykoff C,Turley H,Pastorek J,Taub N,Harris AL,O'Byrne KJ. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003; 21: 47382.
  • 20
    Maseide K,Kandel RA,Bell RS,Catton CN,O'sullivan B,Wunder JS,Pintilie M,Hedley D,Hill RP. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004; 10: 446471.
  • 21
    Span PN,Bussink J,Manders P,Beex LV,Sweep CG. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003; 89: 2716.
  • 22
    Haapasalo JA,Nordfors KM,Hilvo M,Rantala IJ,Soini Y,Parkkila AK,Pastorekova S,Pastorek J,Parkkila SM,Haapasalo HK. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 2006; 12: 4737.
  • 23
    Driessen A,Landuyt W,Pastorekova S,Moons J,Goethals L,Haustermans K,Nafteux P,Penninckx F,Geboes K,Lerut T,Ectors N. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006; 243: 33440.
  • 24
    Chen J,Röcken C,Hoffmann J,Krüger S,Lendeckel U,Rocco A,Pastorekova S,Malfertheiner P,Ebert MP. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005; 54: 9207.
  • 25
    Bui MH,Seligson D,Han KR,Pantuck AJ,Dorey FJ,Huang Y,Horvath S,Leibovich BC,Chopra S,Liao SY,Stanbridge E,Lerman MI, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 80211.
  • 26
    Atkins M,Regan M,McDermott D,Mier J,Stanbridge E,Youmans A,Febbo P,Upton M,Lechpammer M,Signoretti S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 371421.
  • 27
    Sobin LH,Wittekind C. Kidney. In:UICC International Union Against Cancer, eds. TNM classification of malignant tumors, 6th edn. New York: Willey-Liss, 2003. 1935.
  • 28
    Oken MM,Creech RH,Tormey DC,Horton J,Davis TE,McFadden ET,Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 64955.
  • 29
    Fuhrman SA,Lasky LC,Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 65563.
  • 30
    Zavada J,Zavadova Z,Pastorekova S,Ciampor F,Pastorek J,Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993; 54: 26874.
  • 31
    Liao SY,Brewer C,Zavada J,Pastorek J,Pastorekova S,Manetta A,Berman ML,DiSaia PJ,Stanbridge EJ. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994; 145: 598609.
  • 32
    Pantuck AJ,Zeng G,Belldegrun AS,Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9: 464152.
  • 33
    Parker AS,Cheville JC,Lohse CM,Igel T,Leibovich BC,Blute ML. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. Urology 2005; 65: 10905.
  • 34
    Schraml P,Struckmann K,Hatz F,Sonnet S,Kully C,Gasser T,Sauter G,Mihatsch MJ,Moch H. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196: 18693.
  • 35
    Maxwell PH,Wiesener MS,Chang GW,Clifford SC,Vaux EC,Cockman ME,Wykoff CC,Pugh CW,Maher ER,Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 2715.
  • 36
    Krieg M,Haas R,Brauch H,Acker T,Flamme I,Plate KH. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19: 543543.
  • 37
    Hockel M,Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 26676.
  • 38
    Zhong H,Chiles K,Feldser D,Laughner E,Hanrahan C,Georgescu MM,Simons JW,Semenza GL. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 15415.
  • 39
    Rafajova M,Zatovicova M,Kettmann R,Pastorek J,Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 2004; 24: 9951004.
  • 40
    Pantuck AJ,Thomas G,Belldegrun AS,Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol 2006; 33: 60713.
  • 41
    Lam JS,Leppert JT,Yu H,Seligson DB,Dong J,Horvath S,Pantuck AJ,Figlin RA,Belldegrun AS. Expression of the vacular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma. J Clin Oncol 2005; 23: 4538.
  • 42
    Shioi K,Komiya A,Hattori K,Huang Y,Sano F,Murakami T,Nakaigawa N,Kishida T,Kubota Y,Nagashima Y,Yao M. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients. Clin Cancer Res 2006; 12: 733946.
  • 43
    Trastour C,Benizri E,Ettore F,Ramaioli A,Chamorey E,Pouyssegur J,Berra E. HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007; 120: 144350.
  • 44
    Loncaster JA,Harris AL,Davidson SE,Logue JP,Hunter RD,Wycoff CC,Pastorek J,Ratcliffe PJ,Stratford IJ,West CM. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 63949.
  • 45
    Lee S,Shin HJ,Han IO,Hong EK,Park SY,Roh JW,Shin KH,Kim TH,Kim JY. Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Sci 2007; 98: 32933.
  • 46
    Bleumer I,Knuth A,Oosterwijk E,Hofmann R,Varga Z,Lamers C,Kruit W,Melchior S,Mala C,Ullrich S,De MP,Mulders PF, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 98590.
  • 47
    Ivanov SV,Kuzmin I,Wei MH,Pack S,Geil L,Johnson BE,Stanbridge EJ,Lerman MI. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998; 95: 12596601.
  • 48
    Potter C,Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004; 3: 1647.
  • 49
    Rini BI,Jaeger E,Weinberg V,Sein N,Chew K,Fong K,Simko J,Small EJ,Waldman FM. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006; 98: 75662.